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The brain hypothalamus contains certain secreted molecules that are important 
in regulating feeding behaviour1–3. Here we show that nesfatin, corresponding to 
NEFA/nucleobindin2 (NUCB2), a secreted protein of unknown function, is 
expressed in the appetite-control hypothalamic nuclei in rats. 
Intracerebroventricular (i.c.v.) injection of NUCB2 reduces feeding. Rat 
cerebrospinal fluid contains nesfatin-1, an amino-terminal fragment derived 
from NUCB2, and its expression is decreased in the hypothalamic 
paraventricular nucleus under starved conditions. I.c.v. injection of nesfatin-1 
decreases food intake in a dose-dependent manner, whereas injection of an 
antibody neutralizing nesfatin-1 stimulates appetite. In contrast, i.c.v. injection 
of other possible fragments processed from NUCB2 does not promote satiety, 
and conversion of NUCB2 to nesfatin-1 is necessary to induce feeding 
suppression. Chronic i.c.v. injection of nesfatin-1 reduces body weight, whereas 
rats gain body weight after chronic i.c.v. injection of antisense morpholino 
oligonucleotide against the gene encoding NUCB2. Nesfatin-1-induced anorexia 
occurs in Zucker rats with a leptin receptor mutation, and an anti-nesfatin-1 
antibody does not block leptin-induced anorexia. In contrast, central injection of 
α-melanocyte-stimulating hormone elevates NUCB2 gene expression in the 
paraventricular nucleus, and satiety by nesfatin-1 is abolished by an antagonist 
of the melanocortin-3/4 receptor. We identify nesfatin-1 as a satiety molecule 
that is associated with melanocortin signalling in the hypothalamus. 
We attempted to identify any new appetite-regulating molecules by using a 
subtraction-cloning assay of peroxisome proliferator-activated receptor-γ activator 
(troglitazone)-stimulated genes in SQ-5 cells. First, we used a computer-based 
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program (Signal Peptide Prediction, 
http://bioinformatics.leeds.ac.uk/prot_analysis/Signal.html) to search for a signal 
peptide in the coding region of each of the 596 genes cloned in this assay. As most 
hypothalamic secreted molecules also exist in peripheral adipose tissue4, we examined 
whether the genes cloned were expressed in both brain medulloblastoma (HTB185) 
and 3T3-L1 adipocyte cells. Nine genes meeting these criteria were identified, and the 
expression of one gene among those identified was profoundly stimulated by 
troglitazone in SQ-5 cells (Supplementary Fig. 1). Sequencing demonstrated that this 
complementary DNA fragment corresponds to the 5′-untranslated region of the gene 
encoding DNA binding/EF-hand/acidic protein (NEFA) or NUCB2. NUCB2 is 
composed of a signal peptide of 24 amino acids and a protein structure containing 396 
amino acids5. The homology of the amino-acid sequence of NUCB2 is highly 
conserved in humans, mice and rats (87.4% homology to humans and 95.7% to mice). 
Because NUCB2 belongs to a homologous gene family with nucleobindin1 
(NUCB1)6, these two genes might have arisen from a single EF-hand ancestor7. 
NUCB2 and NUCB1 are secreted proteins5–8 but their function remains unknown, 
although these proteins have been suggested to contribute to bone mineralization and 
antibody production9,10. 
Troglitazone does not cross the blood–brain barrier to alter feeding 
behaviour11 and does not change body weights in rodents (Supplementary Fig. 2), but 
the present findings encouraged further investigation into whether the protein deduced 
from this identified gene is present in the hypothalamus. To address this issue, an anti-
NUCB2 antibody (termed NUCB2 Ab-L) was used to perform immunohistochemical 
analyses in rats. This antibody recognizes the whole structure of NUCB2, and its 
detection was not absorbed by the addition of appetite-regulating peptides 
(Supplementary Fig. 3). NUCB2 was expressed in the hypothalamic areas (Fig. 1a–d), 
namely the arcuate nucleus, paraventricular nucleus (PVN) and supraoptic nucleus, 
the lateral hypothalamic area and the zona incerta, which regulate feeding, and also in 
the nucleus tract solitarius (data not shown). Preincubation of the cognate peptide 
with NUCB2 Ab-L abolished staining (data not shown). Analysis of in situ 
hybridization demonstrated that the gene encoding NUCB2 is expressed in the same 
hypothalamic nuclei as those shown by the immunohistochemistory (Fig. 1e). We 
next identified that i.c.v. injection of recombinant protein of NUCB2 decreased food 
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intake (Fig. 1f, g), but no apparent behavioural changes including increased 
locomotion or narcolepsy were noted during the experiments. Conversely, i.c.v. 
injection of IgG from NUCB2 Ab-L stimulated feeding, compared with that induced 
by control IgG (Supplementary Fig. 4). These results indicate that this protein is a 
hypothalamic endogenous molecule that induces anorexia. We therefore refer to this 
protein as nesfatin (for NEFA/nucleobindin2-encoded satiety- and fat-influencing 
protein). 
Post-translational processing of a prohormone produces several fragments or 
peptides through cleavage at specific sites by prohormone convertases (PCs)12, and rat 
NUCB2/nesfatin possesses potential cleavage sites that are flanked by a pair of basic 
amino acids, Lys-Arg or Arg-Arg (Supplementary Fig. 5). The ProP 1.0 prediction 
server13 predicted these sites and showed the highest score for cleavage at the Lys 83-
Arg 84 site, which is conserved among different species5–7. The possible processed 
fragments were designated as follows; nesfatin-1, residues 1–82; nesfatin-2, residues 
85–163; and nesfatin-3, residues 166–396. The structures of nesfatin-2 and nesfatin-3 
are characterized by their possessing putative DNA-binding and leucine-zipper sites 
that bind nucleosomal DNA5,6, but nesfatin-1 does not preserve these sites. We 
produced two different types of antibody, nesfatin Ab24 and Ab301, which 
recognized synthetic nesfatin-1 and nesfatin-3, respectively (Supplementary Fig. 5). 
When monitored by nesfatin-1 ELISA, elution profiles of cerebrospinal fluid extracts 
on high-performance liquid chromatography showed an apparent peak corresponding 
to nesfatin-1 peptide (Supplementary Figs 6 and 7), indicating that nesfatin-1 is a 
secreted fragment. Immunohistochemical analysis with nesfatin Ab24 showed that 
nesfatin-1 was distributed in the hypothalamic nuclei in a similar manner to that 
observed for NUCB2 Ab-L (Supplementary Fig. 8) and was present in the cytoplasm, 
but not the nucleus, of the hypothalamic neurons, where it was co-localized with PC-
3/1 and PC-2 (Fig. 1h). Under conditions of starvation for 24 h, NUCB2 gene 
expression was reduced in the PVN, in which nesfatin-1 concentration was also 
decreased (Fig. 1i, j). No significant changes were observed in other hypothalamic 
nuclei. 
As a prohormone can be processed to generate bioactive fragments14, we next 
estimated the food intake of rats after i.c.v. injection of each of the possible fragments 
derived from NUCB2. Injection of a synthetic peptide identical to nesfatin-1 
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decreased food intake in a dose-dependent manner, and the effects continued for 6 h 
after injection (Fig. 2a, b). In contrast, neither a synthetic peptide corresponding to 
nesfatin-2, a fragment corresponding to nesfatin-3 nor a fragment corresponding to 
nesfatin-2/3 affected appetite (Fig. 2c, d). Subsequently, we found that food intake 
was significantly stimulated after injection of nesfatin Ab24-derived IgG, but not after 
injection of nesfatin Ab301-derived IgG (Fig. 2e). Finally, we found that although 
i.c.v. injection of the intermediate form (residues 1–223) of nesfatin retaining wild-
type Lys 83-Arg 84 significantly reduced feeding, injection of the mutant form of 
nesfatin (Ala 83-Ala 84) did not induce anorexia (Fig. 2f–h), indicating that appetite 
suppression by NUCB2 requires conversion to nesfatin-1. 
In the next experiments we estimated chronological changes in rat body 
weight. In comparison with rats receiving vehicle injection (Fig. 3a, b), rats receiving 
a continuous i.c.v. injection of nesfatin-1 unfailingly showed decreased food intake 
and suppressed body weight gain (at Day 10, 30.4±0.3 versus 12.6±0.7 s.e.m. g, 
respectively). Nesfatin-1 injection also significantly decreased the weights of 
subcutaneous, epididymal and mesenteric fats, but not that of the gastrocnemius 
(Supplementary Fig. 9). Conversely, continuous i.c.v. injection of NUCB2 antisense 
morpholino oligonucleotide diminished the hypothalamic NUCB2 contents 
(Supplementary Fig. 10) and resulted in a consistent increase in appetite. Initially, 
body weight gains remained unchanged until 5 days after injection, but significant 
increases occurred after 6 days (Fig. 3c, d). 
There are complex but integrated interconnections among the hypothalamic 
nuclei in regulating feeding1,2,15. Leptin and pro-opiomelanocortin (POMC)-derived 
α-melanocyte-stimulating hormone are key anorectic molecules in the 
hypothalamus1–3. In Zucker rats possessing a leptin receptor mutation16, significant 
nesfatin-1-induced satiety occurred (Fig. 4a, b). Previous injection of nesfatin Ab24 
eliminated anorexia induced by nesfatin-1, but did not block leptin-induced anorexia 
(Fig. 4c), indicating a possible lack of involvement of hypothalamic leptin signalling 
in the induction of anorexia by nesfatin-1. In contrast, central injection of α-
melanocyte-stimulating hormone stimulated the expression of the PVN gene encoding 
NUCB2 (Supplementary Fig. 11), and previous injection of SHU9119, an antagonist 
specific for the melanocortin 3/4 receptor17, abolished nesfatin-1-induced satiety (Fig. 
4d, e). However, injection of nesfatin-1 did not affect the expression of the genes 
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encoding POMC, agouti-related peptide, neuropeptide Y or corticotropin-releasing 
hormone in the arcuate nucleus and PVN (Supplementary Fig. 12), and nesfatin-1 
stimulated neither cAMP formation nor calcium influx in cells expressing the 
melanocortin-3 or -4 receptor (Supplementary Fig. 13). As the melanocortin-4 
receptor is distributed widely in several brain regions that are plausibly involved in 
the coordinated control of feeding and energy expenditure15,18,19, these findings imply 
the possible involvement of unknown neuronal substances, which are regulated by the 
melanocortin-4 receptor signaling, in mediating nesfatin-1-induced anorexia. Taken 
together, the present studies indicate that hypothalamic nesfatin-1 signalling might 
involve the leptin-independent melanocortin signalling system20. 
We have identified a novel anorexigenic nesfatin corresponding to NUCB2 in 
the hypothalamus that produces a secreted fragment, nesfatin-1. At the carboxy 
terminus matching the nesatin-2/3 fragment, NUCB2 possesses archetypal motifs, 
namely possible calcium-binding and DNA-binding sites5–7. The C-terminal region 
also binds other molecules21. However, the present findings indicate that this C 
terminus is not involved in feeding regulation. In contrast, nesfatin-1 located in the N 
terminus of NUCB2 was indispensable to the induction of satiety, and conversion of 
NUCB2 to nesfatin-1 was essential to induce its activity in vivo. 
The present findings indicate that nesfatin-1 might be a useful target for the 
development of drug therapies to treat obese persons. 
Methods 
Further details are provided in Supplementary Information. 
Subtraction-cloning assay 
With the use of a polymerase chain reaction (PCR)-based subtraction cloning kit22, 
the troglitazone (100 μM)-stimulated genes of SQ-5 cells derived from lung 
carcinomas, which express leptin and its receptor23, were identified. 
Proteins and substances 
A cDNA encoding full-length mouse NUCB2 was subcloned into pMAL-c2x to yield 
a fusion protein with maltose binding protein in Escherichia coli. The intermediate 
forms of nesfatin retaining the wild-type motif Lys 83-Arg 84 or the mutant Lys 83-
Arg 84→Ala 83-Ala 84 (mutations generated by the PCR method) were constructed 
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as glutathione S-transferase fusion proteins with a histidine tag in E. coli transfected 
with the pET41a(+) vector. Peptides for rat nesfatin-1 and nesfatin-2 were synthesized 
by Yanaihara Institute, Inc.
Antibodies 
Antibodies were generated in rabbits against amino-acid sequences of rat NUCB2: 
Ab-L against residues 117–128, Ab24 against residues 24–38, and Ab301 against 
residues 301–314. A Cys residue was added to the C terminus of each peptide. 
Animal experiments 
Without anaesthesia, the test substance (5 μl) was injected into the third ventricle of 
the brain in adult male Wistar rats weighing 200–250 g, as described previously24. 
The experiments involving i.c.v. bolus injection were started 30 min before the 
beginning of the dark cycle (lighting from 6:00 to 18:00), and the experiments for IgG 
injection were started at 10:00 unless otherwise specified. Zucker obese rats were 
purchased from Charles River Laboratory. 
Statistical analysis was performed by analysis of variance, unless otherwise 
mentioned. 
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Figure 1 | Expression of NUCB2 and nesfatin-1 in the rat hypothalamus. a–d, 
Immunohistochemical analysis. a, arcuate nucleus (Arc); b, PVN; c, supraoptic 
nucleus (SON); d, lateral hypothalamic area (LHA). 3V, third ventricle; f, (fornix); 
opt, (optic nerve). e, In situ hybridization with NUCB2 antisense cRNA. Zi, zona 
incerta. f, g, Food intake (n=6–7) after i.c.v. injection of NUCB2: f, dose–response; g, 
time course (open bars, 0 pmol NUCB2; filled bars, 4 pmol NUCB2). h, Double 
immunostaining with nesfatin Ab24 (4-Cl−naphthol in grey) and PC antibodies 
(Alexa594 in red) in the hypothalamus. i, j, Hypothalamic NUCB2 mRNA levels (i, 
n=6–7) and the PVN nesfatin-1 concentrations (j, n=4) in rats fed ad libitum (open 
bars) or starved for 24 h (filled bars). Data are means±s.e.m. Asterisk, P<0.05; two 
asterisks, P<0.01 compared with 0 pmol or ad libitum (Student’s t-test). 
Figure 2 | Nesfatin-1-induced satiety in rats. a, b, Food intake (n=5–8) after i.c.v. 
injection of nesfatin-1; a, dose–response; b, time course (open bars, 0 pmol nesfatin-
1; filled bars, 5 pmol nesfatin-1). c, d, Food intake (n=5–10) after i.c.v. injection of 
each fragment (25 pmol) derived from NUCB2: c, 0–1 h; d, 1–3 h. e, Food intake 
(n=5–7) after i.c.v. injection of 8 μg IgG (open bars, control rabbit IgG; red bars, 
nesfatin Ab24 IgG; black bars, nesfatin Ab301 IgG. f–h, Food intake (n=5–6) after 
i.c.v. injection of each intermediate (5 pmol) with wild-type Lys 83-Arg 84 (WT) or 
mutant Ala 83-Ala 84 (Mut). f, 0–1 h; g, 1–3 h; h, 3–6 h. Data are means±s.e.m. 
Asterisk, P<0.05; two asterisks, P<0.01 compared with 0 pmol, vehicle (V) or control 
IgG. 
Figure 3 | Body weight changes after continuous i.c.v. injection of substances. a, b, 
Daily food intake (a) and body weight gain (b; increment from Day 0) in rats (n=4–5) 
after nesfatin-1 injection (5 pmol daily). Open squares, vehicle; filled squares, 
nesfatin-1. c, d, Daily food intake (c) and body weight gain (d, increment from Day 0) 
in rats (n=4-5) after injection with NUCB2 missense (open squares) or antisense 
(filled squares) morpholino oligonucleotide (MON; 40 μg per day). Antisense (5′-
ATGGTCCTCCACCTCATCTTCAGAG-3′) and 5-missense (5′-
ATCGTGCTCCACGTCATCTACACAG-3′) MONs were purchased from Gene 
Tools. An Alzet osmotic mini-infusion pump was used for continuous injection. Data 
are means±s.e.m. Asterisk, P<0.05; two asterisks, P<0.01 compared with vehicle or 
missense MON. 
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Figure 4 | Nesfatin-1-induced satiety associated with leptin or melanocortin 
signaling. a, b, Food intake in lean (a) and Zucker (b) rats (n=5) after i.c.v. injection 
of 5 pmol nesfatin-1 (open bars, vehicle; filled bars, nesfatin-1). c, Effects of nesfatin 
Ab24 on leptin-induced anorexia (n=6). Vehicle, 5 pmol nesfatin-1 or 5 pmol leptin 
was centrally administered 15 min after i.c.v. injection of Ab24 IgG (8 μg) during the 
dark phase. d, e, Effects of SHU9119 on nesfatin-1-induced anorexia (n=6). Vehicle 
or 5 pmol nesfatin-1 was centrally administered 15 min after i.c.v. injection of 
20 pmol SHU9119. Data are means±s.e.m. Asterisk, P<0.05; two asterisks, P<0.01 
compared with vehicle. 
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